Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer

Condition:   HER2-positive Breast Cancer Intervention:   Other: non-interventional Sponsor:   Chinese Academy of Medical Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Conclusions: The novel lncRNA HOXC-AS3 acts as a miR-3922-5p sponge to upregulate PPP1R1A protein expression, and thus results in promoting breast cancer metastasis. HOXC-AS3 could be a novel therapeutic target for breast cancer therapeutics. PMID: 31797701 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
The FDA approved FoundationOne CDx as a companion diagnostic for alpelisib in combination with fulvestrant for the treatment of men and postmenopausal women with HR+/HER2- PIK3CA-mutated breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
AbstractSynergism in action of tucatinib and trastumab is reported in breast cancer management. However, its molecular basis is yet to be determined. In this context we attempted to provide an explanation at the molecular level by performing in silico experimentation and coupling its result with already available published observations. Our study will provide basis for planning further experimental study for unravelling the truth.
Source: Indian Journal of Clinical Biochemistry - Category: Biochemistry Source Type: research
Condition:   HER2-positive Advanced Breast Cancer Interventions:   Biological: BAT8001 for injection;   Drug: Lapatinib;   Drug: Capecitabine Sponsor:   Bio-Thera Solutions Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Anatomic Stage 0 Breast Cancer AJCC v8;   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC&n...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-positive Advanced Breast Cancer Interventions:   Biological: BAT8001 for injection;   Drug: Lapatinib;   Drug: Capecitabine Sponsor:   Bio-Thera Solutions Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Anatomic Stage 0 Breast Cancer AJCC v8;   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC&n...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-positive Advanced Breast Cancer Interventions:   Biological: BAT8001 for injection;   Drug: Lapatinib;   Drug: Capecitabine Sponsor:   Bio-Thera Solutions Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Anatomic Stage 0 Breast Cancer AJCC v8;   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC&n...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Can a clinicomolecular score reliably predict absolute benefit of chemotherapy in women with HER2-negative, ER-positive breast cancer?JCO Precision Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Research | Study